Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719901 · ClinicalTrials.gov registry record · Phase 1
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00719901: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00719901 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00719901, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects and best dose of obatoclax when given together with bortezomib and to see how well they work in treating patients with relapsed or refractory multiple myeloma. Obatoclax and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obatoclax together with bortezomib may kill more cancer cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG bortezomib
- DRUG obatoclax mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00719901
The ClinicalTrials.gov registry entry for NCT00719901 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00719901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00719901 about?
NCT00719901 is a clinical study titled "Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma". This phase I/II trial is studying the side effects and best dose of obatoclax when given together with bortezomib and to see how well they work in treating patients with relapsed or refractory multiple myeloma. Obatoclax and bortezomib may stop the growth of cancer cells by blocking some of the enzy...
What is the current status of trial NCT00719901?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2008-07. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00719901?
The interventions under investigation include: laboratory biomarker analysis (OTHER), bortezomib (DRUG), obatoclax mesylate (DRUG).
Who is sponsoring clinical trial NCT00719901?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.